Japanese pharmaceutical company headquartered in Tokyo, formed in 2008 from the merger of Kyowa Hakko Kogyo, founded in 1949, with Kirin Pharma and renamed Kyowa Kirin in 2019, part of the Kirin Holdings group. Specialises in antibody engineering and biologics with its POTELLIGENT defucosylation technology, and develops and markets medicines in nephrology, oncology, immunology and neurology and rare disease, including burosumab, mogamulizumab and darbepoetin alfa, with research and manufacturing sites in Japan, the United States and Europe.
Aucun commentaire disponible.
Laissez votre note & commentaire